Israel’s Sight Diagnostics said on Wednesday it raised $71 million in private funding to expand sales of its finger-prick blood analyzer and support research and development.
Koch Disruptive Technologies, Longliv Ventures, which is part of the CK Hutchison Group, and Israel’s OurCrowd participated in the round, which brings Sight’s total funding to more than $124 million.
The funds will support the expansion of commercial operations and advance R&D into the detection of new diseases as well as the blood factors affecting COVID-19 severity.
Sight is also working with pharmaceutical companies, including Pfizer, to provide support for different treatment and therapy. Since early in the pandemic, Sight has deployed its analyzer in healthcare facilities fighting COVID-19, including Israel’s Sheba Tel Hashomer. (JPost / VFI News)
Originally posted at vfinews.com